# Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.

**Tumor:** Cáncer de esófago
**Autores:** Zhang X
**Revista:** BMC Cancer (2020)
**PMID:** 32143580 | **PMCID:** PMC7060643
**DOI:** [10.1186/s12885-020-6669-y](https://doi.org/10.1186/s12885-020-6669-y)
**Fuente:** PubMed Central (open access)

## Relevancia
Cáncer de esófago/UGE tras quimiorradioterapia CROSS o quimioterapia FLOT: aborda pCR ganglionar, supervivencia según yp-stage y patrones de diseminación nodal. Análogo a mama: el ypN0 es el factor pronóstico independiente más robusto tras tratamiento neoadyuvante.

## Abstract
After neoadjuvant chemoradiotherapy (nCRT) for esophageal cancer, high pathologically complete response (pCR) rates are being achieved especially in patients with squamous cell carcinoma. An active surveillance strategy has been proposed for SCC patients with clinically complete response after nCRT. The aim of this study is to assess the accuracy of response evaluations after nCRT based on the preSANO trial, including PET-CT, endoscopy with bite-on-bite biopsies and EUS with FNA. If the current study shows that major locoregional residual disease (>10% residual carcinoma or any residual nodal disease) can be accurately detected, a prospective trial will be conducted comparing active surveillance with standard esophagectomy.

## Acceso
Disponible en PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC7060643/

---
*Datos de PubMed. Citar: doi 10.1186/s12885-020-6669-y*
